OssDsign AB

OssDsign AB has reported a 56.6% increase in revenue to SEK 46.5 million in Q2 2025, driven by a robust gross margin and strong growth in its medical device business.

OssDsign AB has reached a significant milestone, treating 10,000 patients in the US with its innovative bone regeneration product, OssDsign Catalyst.